Clinical Utility of Selinexor/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: A Review of Current Evidence and Patient Selection

Multiple myeloma (MM) is one the most common hematological malignancies, and despite the survival prolongation offered by proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs) and anti-CD38 monoclonal antibodies, the need for novel agents is prominent. Selinexor is a first-in-class, oral, sele...

Descripción completa

Detalles Bibliográficos
Autores principales: Malandrakis, Panagiotis, Ntanasis-Stathopoulos, Ioannis, Gavriatopoulou, Maria, Terpos, Evangelos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7335864/
https://www.ncbi.nlm.nih.gov/pubmed/32669858
http://dx.doi.org/10.2147/OTT.S227166

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7335864/
https://www.ncbi.nlm.nih.gov/pubmed/32669858
http://dx.doi.org/10.2147/OTT.S227166

Ejemplares similares